This move is archived. Current quotes and coverage live on the stock page.
Follow ALNY
Alnylam Pharmaceuticals is seeing a significant rise in its stock price, thanks to positive developments in the RNA interference therapeutics market.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) shares are up 2.84%, closing at CA$246.37. This increase follows encouraging news about regulatory changes for rare diseases and the growing market for RNA interference therapies.
Investor takeaway: Investors are likely feeling optimistic about Alnylam’s position in the rapidly growing RNA interference therapeutics market, supported by recent FDA initiatives aimed at advancing drug development for rare diseases.
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$20.89B
P/E
7.9x
52W high
$479.79
52W low
$154.30
1W change
-5.49%
Beta
0.44
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Nov 9, 2026
Wall Street analysts forecast ALNY stock price to rise 94.0% over the next 12 months.
Consensus
Buy4.17 / 5.00
Avg. Target
C$302.56
+94.0% Upside
Previously C$302.48 on Nov 4, 2026
Current Price
C$155.94
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
90.9%
Annualized
90-Day Vol
85.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$130.44
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$146.93 | C$107.36 – C$201.08 |
| 60 trading days | C$138.44 | C$88.83 – C$215.76 |
| 90 trading days | C$130.44 | C$75.75 – C$224.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Alnylam’s market cap reaches CA$32.06 billion.
With a P/E ratio of 41.66, Alnylam's valuation shows investor confidence in its growth prospects, particularly in the expanding RNAi therapeutics market.
Bull case
The FDA's upcoming workshop on evidence standards for rare diseases could lead to more flexible regulatory pathways, which would benefit Alnylam's pipeline. Additionally, the RNA interference therapeutics market is expected to grow significantly, enhancing Alnylam's revenue potential.
Bear case
Despite the positive outlook, investors should stay cautious about possible pricing pressures and margin compression that could affect Alnylam's profitability. The company's dependence on a few key products raises concerns about its long-term sustainability.
Positive Regulatory Developments
The FDA, in partnership with the Duke-Margolis Institute, is planning a workshop focused on evidence standards for rare disease clinical investigations. This initiative could create a more favorable regulatory environment for Alnylam's therapies, which often face challenges due to the small patient populations in rare diseases.
Expanding Market Potential
The global RNA interference therapeutics market is projected to reach USD 31.4 billion by 2035, growing at a CAGR of 18.5%. This growth is driven by advancements in genetic research and increased investment in precision medicine, positioning Alnylam as a key player in this expanding market.
Financial Metrics and Investor Sentiment
Alnylam's stock performance reflects strong investor sentiment, with a market cap of CA$32.06 billion and a P/E ratio of 41.66. While the stock's valuation indicates confidence in its growth trajectory, potential risks related to pricing pressures and market competition remain.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
